CG Oncology, Inc.
CGONHeld by 13 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying13 funds opened new positions. Next phase2 readout (Ivaltinostat): Jun 2026. Short interest: 12.2% of float.
Held by 13 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying13 funds opened new positions. Next phase2 readout (Ivaltinostat): Jun 2026. Short interest: 12.2% of float.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.